JP5528461B2 - 心不全の評価におけるビグリカンの使用 - Google Patents

心不全の評価におけるビグリカンの使用 Download PDF

Info

Publication number
JP5528461B2
JP5528461B2 JP2011531396A JP2011531396A JP5528461B2 JP 5528461 B2 JP5528461 B2 JP 5528461B2 JP 2011531396 A JP2011531396 A JP 2011531396A JP 2011531396 A JP2011531396 A JP 2011531396A JP 5528461 B2 JP5528461 B2 JP 5528461B2
Authority
JP
Japan
Prior art keywords
biglycan
marker
heart failure
markers
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011531396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506031A (ja
JP2012506031A5 (enExample
Inventor
ウィーンヒュース−テーレン，ウルズラ−ヘンリーケ
アラブ，サラ
ブロック，ディルク
エミリ，アンドリュー
グラモリーニ，アンソニー
ヘス，ゲオルク
ヒューディク，ヘンドリーク
リウ，ピーター
マクレナン，デビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2012506031A publication Critical patent/JP2012506031A/ja
Publication of JP2012506031A5 publication Critical patent/JP2012506031A5/ja
Application granted granted Critical
Publication of JP5528461B2 publication Critical patent/JP5528461B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011531396A 2008-10-17 2009-10-15 心不全の評価におけるビグリカンの使用 Expired - Fee Related JP5528461B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08018196 2008-10-17
EP08018196.9 2008-10-17
PCT/EP2009/007399 WO2010043393A1 (en) 2008-10-17 2009-10-15 Use of biglycan in the assessment of heart failure

Publications (3)

Publication Number Publication Date
JP2012506031A JP2012506031A (ja) 2012-03-08
JP2012506031A5 JP2012506031A5 (enExample) 2012-07-05
JP5528461B2 true JP5528461B2 (ja) 2014-06-25

Family

ID=40418863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531396A Expired - Fee Related JP5528461B2 (ja) 2008-10-17 2009-10-15 心不全の評価におけるビグリカンの使用

Country Status (6)

Country Link
US (1) US20110165591A1 (enExample)
EP (1) EP2347265A1 (enExample)
JP (1) JP5528461B2 (enExample)
CN (1) CN102187228A (enExample)
CA (1) CA2738417A1 (enExample)
WO (1) WO2010043393A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107110871B (zh) * 2014-10-29 2019-09-27 豪夫迈·罗氏有限公司 用于死亡的风险预测的生物标志物
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
CN115236340A (zh) * 2022-07-28 2022-10-25 复旦大学附属中山医院 S100a4、s100a8/a9和s100a12作为扩张型心肌病生物标记物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
DE3922873A1 (de) * 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US6333397B1 (en) * 1989-04-25 2001-12-25 Roche Diagnostics Gmbh Monoclonal antibodies to troponin T and their production
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ATE281648T1 (de) * 1995-04-18 2004-11-15 Biosite Diagnostics Inc Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
US6610480B1 (en) * 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US20090233270A9 (en) * 2000-08-02 2009-09-17 St Croix Brad Secreted and cytoplasmic tumor endothelial markers
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
MXPA06005950A (es) * 2003-11-25 2006-07-06 Novartis Ag Biomarcadores para determinar la eficacia del tratamiento con calcitonina y hormona paratiroides.
WO2006034356A2 (en) 2004-09-20 2006-03-30 The Board Of Trustees Of The Leland Stanford Junior University Cardiac pressure overload associated genes
EP1929295A4 (en) * 2005-08-30 2010-03-17 Biosite Inc USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
EP1837659B1 (en) * 2006-03-24 2010-06-09 F. Hoffman-la Roche AG Means and methods for the differentiation of acute and chronic myocardial necrosis in symptomatic patients
US20100143949A1 (en) * 2006-10-31 2010-06-10 George Mason Intellectual Properties, Inc. Biomarkers for colorectal cancer
HU0700024D0 (en) * 2007-01-11 2007-03-28 Mta Szegedi Biolog Koezpont Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten

Also Published As

Publication number Publication date
EP2347265A1 (en) 2011-07-27
CN102187228A (zh) 2011-09-14
US20110165591A1 (en) 2011-07-07
WO2010043393A1 (en) 2010-04-22
WO2010043393A8 (en) 2011-02-24
CA2738417A1 (en) 2010-04-22
JP2012506031A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
CA2671298C (en) Use of igfbp-7 in the assessment of heart failure
JP5592487B2 (ja) 心不全の評価におけるミメカンの使用
JP5524182B2 (ja) 心不全の評価におけるｓｆｒｐ−３の使用
JP5081930B2 (ja) 心不全の評価におけるｓｌｉｍ−１の使用
JP2012524282A (ja) 心不全のマーカーとしてのエンドスタチンの使用
JP2016525693A (ja) 心不全の評価におけるアルファ−クリスタリンｂ（ｃｒｙａｂ）の使用
JP5528461B2 (ja) 心不全の評価におけるビグリカンの使用
HK1240320A1 (en) Use of igfbp-7 in the assessment of heart failure
HK1224375B (en) Use of mimecan in the assessment of heart failure
HK1138373A (en) Use of igfbp-7 in the assessment of heart failure
HK1162069A (en) Use of biglycan in the assessment of heart failure
HK1140543A (en) Use o slim-1 in the assessment of heart failure
HK1152564A (en) Use of sfrp-3 in the assessment of heart failure
HK1172686A (en) Use of mimecan in the assessment of heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140415

R150 Certificate of patent or registration of utility model

Ref document number: 5528461

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees